Does J2562 require prior authorization?

Yes, J2562 requires prior authorization (medium confidence). Conditional coverage; review criteria to confirm PA need.

What is the Medicare reimbursement rate for J2562?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

Backwork Sign up free

`J2562`, Injection, plerixafor, 1 mg

HCPCS/CPT

Prior Authorization

Prior Auth Required

Conditional coverage; review criteria to confirm PA need (medium confidence)

Medicare Pricing

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Documentation Required

Documentation that the requested medication will be used to mobilize hematopoietic stem cells for collection prior to transplantation (documentation of planned autologous transplantation or intent to collect for transplant).

Clinical notes addressing prior mobilization attempts and rationale for plerixafor (particularly relevant for poor mobilizers or re-mobilization scenarios), if applicable.

When billing, use applicable CPT/HCPCS codes (e.g., J2562 for plerixafor 1 mg) and the appropriate ICD-10 diagnosis code from the covered list corresponding to the treated hematologic malignancy.

Documentation that the requested medication will be administered after the member has received a granulocyte-colony stimulating factor (G-CSF) (e.g., filgrastim) or after chemo-mobilization (dates and agents used for prior G-CSF or chemo-mobilization).

Key Coverage Criteria

Aetna considers plerixafor (Mozobil or generic plerixafor) injection medically necessary when all of the following criteria are met: The requested medicaton will be used to mobilize hematopoietic stem cells for collection prior to transplantation; and The requested medication will be administered after the member has received a granulocyte-colony stimulating factor (G-CSF) (e.g., filgrastim) or chemo-mobilization; and The requested medication will not be used beyond 4 consecutive days or after c [...]
Continuation of plerixafor (Mozobil) injection therapy is medically necessary for all members (including new members) who meet all initial medical necessity selection criteria.
FDA-approved indication (background): Mozobil is indicated in combination with granulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma or multiple myeloma.
HCPCS code covered if selection criteria are met: J2562 Injection, plerixafor, 1 mg [Mozobil].
ICD-10 codes covered if selection criteria are met: C82.00 - C82.99; C84.00 - C84.49; C84.a0 - C84.99; C85.10 - C85.99; C86.0 - C86.6; C91.40 - C91.42; C96.0 - C96.4; C96.a - C96.9; Other malignant neoplasms of lymphoid and histiocytic tissue; C83.00 - C83.99; C84.60 - C84.79; C88.4; C88.8 - C90.32 (Malignant immunoproliferative diseases and multiple myeloma and malignant plasma cell neoplasms).
Compendial use listed: Hematopoietic cell transplantation.

9 Active Policies

BCBSM-2036644-FD6C056387, AIM MEDICAL POLICY - MOZOBIL (PLERIXAFOR) (RETIRED AS OF 02/02/2023)

BCBSND-PLERIXAFOR-MOZOBIL-E53D788990, Plerixafor Mozobil

BCBSNJ-DRUGS-065-E80E3BF7E6, Mozobil (Plerixafor Injection)

HEALTHNET_OR-HNOR-PLERIXAFOR-MOZOBIL-CP-PHAR-323-375EE8A9C1, Plerixafor (Mozobil); CP.PHAR.323

AETNA-CPB-0779, Plerixafor

BCBSOK-RX502.061, Oncology Medications

BCBSIL-RX502.061, Oncology Medications

BCBSMT-RX502.061, Oncology Medications

BCBSNM-RX502.061, Oncology Medications

Have a follow-up question?

Ask Backwork about documentation requirements, denial risks, or coverage in your state.

Ask Backwork about J2562 Sign up free

J2562, Injection, plerixafor, 1 mg